Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Multi-center, De-centralized, Dose Selection Study of Autologous CD19-directed Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

NCT03938987 is registered in ClinicalTrials.gov with University of Alberta as lead sponsor.

NCT NCT03938987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03938987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Multi-center, De-centralized, Dose Selection Study of Autologous CD19-directed Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Lead sponsor
University of Alberta
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 3, 2021
Completion date
December 31, 2027
Enrollment
63 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed adult all, relapsed non hodgkin lymphoma, relapsed pediatric all